ReportWire

Tag: investment management company

  • Artisan Mid Cap Fund Maintains Its Confidence in Argenx’s (ARGX) VYVGART

    [ad_1]

    Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Fund”.  A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. US equities ended a record year with robust fourth-quarter gains. The Fund’s Investor Class, ARTMX, delivered -0.44%, the Advisor Class, APDMX, delivered -0.37%, and the Institutional Class, APHMX, delivered -0.35% in the fourth quarter compared to -3.70% for the Russell Midcap® Growth Index. Continued strength in information technology (IT) and health care contributed to the performance during the quarter. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.

    In its fourth-quarter 2025 investor letter, Artisan Mid Cap Fund highlighted stocks like Argenx SE (NASDAQ:ARGX). Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company and a leading contributor to the fund’s quarterly performance. On February 23, 2026, Argenx SE (NASDAQ:ARGX) stock closed at $826.25 per share. One-month return of Argenx SE (NASDAQ:ARGX) was -0.83%, and its shares gained 31.96% over the past 52 weeks. Argenx SE (NASDAQ:ARGX) has a market capitalization of $51.131 billion.

    Artisan Mid Cap Fund stated the following regarding Argenx SE (NASDAQ:ARGX) in its fourth quarter 2025 investor letter:

    “Our top contributors in Q4 were Argenx SE (NASDAQ:ARGX), Coherent and Insmed. Argenx is a commercial-stage biotechnology company with a first-in-class auto-immune therapy, VYVGART®, approved for myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy. In its latest earnings report, VYVGART® sales nearly doubled YoY, rising 96% and bringing annualized sales to over $4 billion, supported by growth in new patient uptake following the launch of its prefilled syringe formulation. Late in the quarter, the stock pulled back after the company discontinued a mid stage trial to treat thyroid eye disease due to a lack of efficacy. While this took away some of the upside for the quarter, we continue to view additional indications for VYVGART® as a compelling opportunity, with the drug currently being studied to treat more than a dozen other diseases.”

    Is argenx SE (ARGX) the Best Cancer Stock to Invest in for Long-Term Gain?

    Argenx SE (NASDAQ:ARGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 47 hedge fund portfolios held Argenx SE (NASDAQ:ARGX) at the end of the fourth quarter, compared to 50 in the previous quarter. While we acknowledge the potential of Argenx SE (NASDAQ:ARGX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    [ad_2]

    Source link

  • Bristol Gate US Equity Strategy: NVDA’s Demand Today is Broadcom’s (AVGO) Opportunity Tomorrow

    [ad_1]

    Bristol Gate Capital Partners, an investment management company, published its Q3 2025 investor letter for the “US Equity Strategy”. A copy of the letter can be downloaded here. The strategy underperformed the benchmark, the S&P 500® Total Return Index, this quarter, but still surpassed the index in dividend growth. The underperformance was due to a lack of significant exposure to the AI/TMT sector or the Value sector, which provides advantages stemming from the Federal Reserve’s rate cut. The portfolio returned 15% dividend growth over the trailing 12 months, driven by the strong underlying fundamentals. In addition, please check the fund’s top five holdings to know its best picks in 2025.

    Prediction Market powered by

    In its third-quarter 2025 investor letter, Bristol Gate US Equity Strategy highlighted stocks such as Broadcom Inc. (NASDAQ:AVGO). Broadcom Inc. (NASDAQ:AVGO) is a leading technology company that designs and develops various semiconductor and infrastructure software solutions. The one-month return of Broadcom Inc. (NASDAQ:AVGO) was -8.31%, and its shares gained 50.90% of their value over the last 52 weeks. On December 30, 2025, Broadcom Inc. (NASDAQ:AVGO) stock closed at $349.85 per share, with a market capitalization of $1.659 trillion.

    Bristol Gate US Equity Strategy stated the following regarding Broadcom Inc. (NASDAQ:AVGO) in its third quarter 2025 investor letter:

    “Broadcom Inc. (NASDAQ:AVGO) reported its third quarter results on September 4, which beat analyst expectations for both revenue and earnings per share. However, the highlight of the quarter was the addition of a fourth significant customer for its XPU (custom AI accelerator) products, who has placed over $10 billion in orders to be shipped in Q326. The combination of continued growth from the existing three customers and the addition of this fourth major customer will drive a material improvement in Broadcom’s AI revenue growth in fiscal 2026 compared to the previous outlook. Management now expects 2026 AI revenue growth to exceed fiscal 2025’s 50-60% rate. In addition to the four customers for which it has secured orders, the company is working on projects with three other hyperscalers. Our “NVDA’s demand today is AVGO’s opportunity tomorrow” thesis continues to play out in the hyperscaler market where demand for custom AI accelerators continues to grow as each of them journeys towards compute self-sufficiency. The company’s overall backlog now stands at $110B, with over 50% from semiconductors.”

    AVGO Stock: A Strong Buy Pick Backed by Robust Cash Flow and Dividend Growth

    Broadcom Inc. (NASDAQ:AVGO) is in the 12th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 183 hedge fund portfolios held Broadcom Inc. (NASDAQ:AVGO) at the end of the third quarter, which was 156 in the previous quarter. In the fiscal third quarter of 2025, Broadcom Inc. (NASDAQ:AVGO) reported record revenue of $16 billion, up 22% year-over-year. While we acknowledge the potential of Broadcom Inc. (NASDAQ:AVGO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    [ad_2]

    Source link

  • Moody’s (MCO) Fell on Increasing Competition in the AI Sector

    [ad_1]

    Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Premier Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The third quarter was a standout period for US equities, led by optimism over the Federal Reserve’s dovish pivot and the ongoing boom in artificial intelligence (AI). The S&P 500® Index and the Nasdaq Composite surged, representing technology’s relentless momentum.  In the quarter, the strategy returned +6.41% net of fees, compared to +8.00% and +8.12% returns for the Russell 1000 Index and the S&P 500 Index, respectively. In addition, please check the fund’s top five holdings to know its best picks in 2025.

    In its third-quarter 2025 investor letter, Mar Vista U.S. Quality Premier Strategy highlighted stocks such as Moody’s Corporation (NYSE:MCO). Moody’s Corporation (NYSE:MCO) is a leading integrated risk assessment firm. The one-month return of Moody’s Corporation (NYSE:MCO) was -3.16%, and its shares gained 3.60% of their value over the last 52 weeks. On October 8, 2025, Moody’s Corporation (NYSE:MCO) stock closed at $490.09 per share, with a market capitalization of $87.902 billion.

    Mar Vista U.S. Quality Premier Strategy stated the following regarding Moody’s Corporation (NYSE:MCO) in its third quarter 2025 investor letter:

    “Moody’s Corporation (NYSE:MCO) stock declined for the quarter on concerns of a growing AI arms race among competitors. In mid-September, FactSet reported slowing growth and commented that increasing competitive dynamics from start-ups, new competitors, and traditional competitors may pressure margins. Moody’s Analytics segment has been early and aggressive in rolling out agentic artificial intelligence models. Their strategy aims to expand the company’s ecosystem where customers can leverage Moody’s data, analytics, and AI tools within their own workflows. We expect Moody’s AI investments will further imbed its services into the operations of banks, insurance companies, and asset managers, further expanding the company’s economic moat.”

    Is Moody’s Corporation (MCO) The Best Financial Sector Dividend Stock To Buy Right Now?

    Moody’s Corporation (NYSE:MCO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 82 hedge fund portfolios held Moody’s Corporation (NYSE:MCO) at the end of the second quarter, the same as in the previous quarter. While we acknowledge the potential of Moody’s Corporation (NYSE:MCO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    [ad_2]

    Source link

  • Is Cellebrite (CLBT) Poised to Re-Accelerate in 2026?

    [ad_1]

    Voss Capital, LLC, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Voss Capital’s funds, Voss Value Fund, LP, and the Voss Value Offshore Fund, Ltd returned +1.0% and +0.6% to investors net of fees and expenses respectively, in the second quarter compared to a +8.5% return for the Russell 2000 Index, +5.0% return for the Russell 2000 Value Index, and +10.9% return for the S&P 500 Index. The Voss Value Master Fund’s total gross exposure stood at 165.6% and the net long exposure was 68.9% as of June 30, 2025. The weight of the fund’s top 10 longs was 66.9% and the top 10 shorts were -40.8%. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

    In its second-quarter 2025 investor letter, Voss Capital highlighted stocks such as Cellebrite DI Ltd. (NASDAQ:CLBT). Headquartered in Petah Tikva, Israel, Cellebrite DI Ltd. (NASDAQ:CLBT) is a software company that develops solutions for legally sanctioned investigations. The one-month return of Cellebrite DI Ltd. (NASDAQ:CLBT) was 17.81%, and its shares lost 2.89% of their value over the last 52 weeks. On August 27, 2025, Cellebrite DI Ltd. (NASDAQ:CLBT) stock closed at $16.47 per share, with a market capitalization of $4.026 billion

    Voss Capital stated the following regarding Cellebrite DI Ltd. (NASDAQ:CLBT) in its second quarter 2025 investor letter:

    “Cellebrite DI Ltd. (NASDAQ:CLBT), the leading provider of digital forensics software used by law enforcement and government agencies worldwide, reported results that were about as constructive as we could have hoped for given the stock’s 50% drop from earlier in the year. Management cut revenue guidance by just 1% and raised EBITDA guide by 2%, while ARR was trimmed by ~4% (or $20M) due primarily to federal budget timing issues. While the ARR reset is concerning on the surface, we believe it is largely a prudent derisking exercise under the company’s new CFO, with cuts significant enough to reset expectations lower but not so large as to suggest systemic weakness. This leaves the stock positioned for potential beats in the back half of the year as federal contracts normalize. Importantly, gross margins remain exceptionally strong relative to software peers (subscription margins above 90%), billings growth has reaccelerated to 25% and now exceeds revenue and ARR growth, and free cash flow continues to outpace EBITDA by more than 30% thanks to low capex, favorable working capital dynamics, and R&D tax credits— underscoring CLBT’s pristine quality of earnings.

    [ad_2]

    Source link